Pharma

Your Article Summary

See Latest Articles

Synthon announces European approvals for generic Montelukast February 2009
Synthon, 03/06/09

Synthon is pleased to announce that it has successfully completed multiple decentralized procedures for its newest product within its comprehensive portfolio: Montelukast. Regulatory clearance has been obtained for Synthon's product in sixteen European countries. Registration has been obtained for multiple dosage forms including a filmcoated tablet, intended for adults aged 15 years and above, and a chewable dosage form, intended for children aged 2 -14 years. Synthon' s product is a fully generic and bioequivalent version of the oral anti-asthma and anti-allergy agent Montelukast. Synthon will market Montelukast through its marketing partners in 4 and 5 mg chewable tablets and 10 mg filmcoated tablets.

Today in Drug/Product Approvals...keeping you current

Receive free subspecialty "5-minute updates" via email

FDA Approves Gardasil to Prevent Genital Warts in Males. Agency Also Approves Bivalent HPV Vaccine for Girls, Young Women
American Family Physician, 10/27/09

Novartis receives FDA approval for Valturna®, a single-pill combination of valsartan and aliskiren, to treat high blood pressure
Novartis, 09/18/09

Salix Receives FDA Marketing Approval for Metozolv
Salix Pharmaceuticals, 09/09/09

See All of Drug/Product Approvals